CRISPR Therapeutics AG
Every calculator, already run for CRSP
Open the full toolkit →You have the numbers on CRSP. Get the argument.
A written report on which of these readings actually decide the outcome for CRISPR Therapeutics AG, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
22 analysts covering CRSPOwnership & short interest
About CRISPR Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for auto…
CRSP — frequently asked
Is CRSP a buy right now?
Wall Street's consensus rating on CRISPR Therapeutics AG is Buy across 22 analysts, with a mean price target of $75.24 (+43% vs. the current $52.45). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Compare CRISPR Therapeutics AG against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For CRISPR Therapeutics AG
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full CRSP research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on CRISPR Therapeutics AG, in minutes. 3 free reports included with every account — no credit card required.